Press Releases for RDEA

Press Releases
Ardea Biosciences Reports Recent Accomplishments and Announces Second Quarter and Year-to-Date 2009 Financial Results
Ardea Biosciences Initiates Phase 2b Clinical Trial of RDEA594, Lead Product Candidate for the Treatment of Gout
Ardea Biosciences to Present at the 4th Annual Piper Jaffray Europe Conference
Gout cases increasing in United States
Ardea Biosciences Announces Positive Interim Phase 2a Results for Lead Gout Drug, RDEA594
Ardea Biosciences to Present Preclinical and Phase 1 Data on its Lead Gout Product Candidate, RDEA594, at the Annual European Congress of Rheumatology
Tang Capital Partners, LP and Perceptive Life Sciences Master Fund Ltd. Urge the Shareholders of Penwest Pharmaceuticals Co. To Vote for Their Shareholder Proposals
Ardea Biosciences Reports Recent Accomplishments and First Quarter 2009 Financial Results
Ardea Biosciences and Bayer HealthCare Enter into Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Cancer
Ardea Biosciences Announces Positive Results from a Phase 1 Study of Lead Hyperuricemia and Gout Candidate, RDEA594 and a Phase 2a Study of RDEA594’s Prodrug, RDEA806
Ardea Biosciences Announces Investor and Analyst Event Participants and Webcast Information
Ardea Biosciences to Present Preclinical Multi-Drug Combination Synergy Data on its Lead MEK Inhibitor, RDEA119, at the American Association for Cancer Research 100th Annual Meeting
Ardea Biosciences Announces Investor and Analyst Event
Ardea Biosciences Reports Progress of Clinical Development Programs; Announces Fourth Quarter and Full-Year 2008 Financial Results and Provides 2009 Outlook and Financial Guidance
Ardea Biosciences to Present at the Cowen & Co. 29th Annual Health Care Conference
Ardea Biosciences Announces Positive Results from a Phase 1 Study of RDEA594
Ardea Biosciences Announces $30.6 Million Private Placement
Ardea Biosciences to Present at the 20th Annual Piper Jaffray Healthcare Conference
Ardea Biosciences Secures $8 Million Growth Capital Loan
Ardea Biosciences Announces Progress of Clinical Development Programs and Reports Third Quarter and Year-to-Date 2008 Financial Results
Ardea Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference and the Lazard Capital Markets 5th Annual Healthcare Conference
Ardea Biosciences Presents Additional Phase 2a and Preclinical Data on its Lead HIV Product Candidate, RDEA806, at the 48th Annual ICAAC/IDSA 46th Annual Meeting
Ardea Biosciences Presents Preliminary Data from a Phase 1 Study of RDEA594 at the 2008 ACR/ARHP Annual Scientific Meeting
NASDAQ OMX Group Hosts Its First Middle East Investor Conference in Dubai to Provide Issuers With Access to Gulf Investors; Exchange Will Ring NASDAQ Opening Bell From Dubai On November 20
Ardea Biosciences to Present Clinical Data on its Lead MEK Inhibitor, RDEA119, at the ASCO-NCI-EORTC 2nd Annual Meeting on Molecular Markers in Cancer
Ardea Biosciences Presents Preclinical Data on its Lead MEK Inhibitor, RDEA119, Demonstrating Synergy with Other Anti-Cancer Agents in Multiple Tumor Types
Ardea Biosciences Awarded Composition of Matter Patent Covering RDEA806, Its Lead NNRTI for the Treatment of HIV
Ardea Biosciences Initiates a Phase 1/2 Study of RDEA119, its Lead MEK Inhibitor, in Combination with Nexavar(R) (sorafenib) in Patients with Advanced Cancer
Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting
Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
Ardea Biosciences Announces Progress of Clinical Development Programs and Reports Second Quarter and Year-to-Date 2008 Financial Results
Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Ardea to Present Data on Lead HIV Candidate, RDEA806, at ICAAC/IDSA Joint Meeting
Ardea to Present Data on Lead HIV Candidate, RDEA806, at XVII International AIDS Conference
Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
Craig Johnson Joins Ardea Biosciences' Board of Directors
Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology
Ardea to Present Data on Inflammation Programs at 2008 Annual European Congress of Rheumatology
Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis - May 27 2008 12:59AM
Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 - May 27 2008 12:56AM
Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008 - May 27 2008 12:53AM
Ardea Biosciences Announces Upcoming Corporate Meetings - May 27 2008 12:53AM
Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results - Jun 2 2008 2:31AM
Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences